The Week in Review in Drug Pricing

The hills are alive with the sound of drug pricing reform.
 
Welcome to the Week in Review in Prescription Drug Pricing!
 
1. Laboratories for lower drug prices 

  • States aren’t waiting around for the federal government to act on drug prices. Maryland wants a board to hold Big Pharma accountable. — (The Baltimore Sun

 
2. Close the Big Pharma Tax Loophole

  • Sen. Jeanne Shaheen (D-NH) introduced legislation to prohibit pharmaceutical corporations from claiming tax deductions for direct-to-consumer advertising expenses. Big Pharma spent $6 billion on direct-to-consumer ads in 2016 alone. — (STAT News


3. Azar on the move


4. Pfizer Pflops

  • Pfizer hiked the prices on 41 prescription drugs this week, in blatant disregard for the financial health and wellbeing of all Americans. It’s not OK. — (P4AD
      

5.  ✈️✈️✈️

  • Are the executives at Pfizer, Johnson & Johnson, and Novartis doing a lot of “innovating” on their private airplanes? — (Twitter)